#2-93E. Streamlining Safety: The 2025 BSR Guideline for csDMARD Prescription and Monitoring (Rheumatology, 2025)

Is frequent blood monitoring always necessary for stable rheumatic patients? This episode explores a pivotal shift in the management of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) through the "2025 British Society for Rheumatology guideline." Updating the 2017 standards, this comprehensive document covers the entire life course—from pediatrics to adulthood—and integrates modern guidance on vaccinations, comorbidity management, and newer agents like voclosporin. The most significant clinical evolution is the recommendation for "risk-stratified monitoring," which allows clinicians to extend blood test intervals to every three months or longer for stable, low-risk patients, moving away from rigid monthly schedules. However, critical appraisal is required, as the authors acknowledge that due to a lack of randomized trials comparing specific monitoring strategies, these recommendations largely rely on observational data and expert consensus. This guideline is vital for physicians as it offers a validated framework to reduce unnecessary testing, optimizing healthcare resource utilization and patient convenience without compromising safety in daily practice.

Citation: Bechman K, et al. The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs. Rheumatology. 2025. DOI: 10.1093/rheumatology/keaf522

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.